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Background: Tumour-specific radiosensitising treatments may enhance the efficacy of radiotherapy without exacerbating side
effects. In this study we determined the radiation response following depletion or inhibition of TOPK, a mitogen-activated protein
kinase kinase family Ser/Thr protein kinase that is upregulated in many cancers.
Methods: Radiation response was studied in a wide range of cancer cell lines and normal cells using colony formation assays. The
effect on cell cycle progression was assessed and the relationship between TOPK expression and therapeutic efficacy was studied
in a cohort of 128 prostate cancer patients treated with radical radiotherapy.
Results: TOPK knockdown did not alter radiation response in normal tissues, but significantly enhanced radiosensitivity in cancer
cells. This result was recapitulated in TOPK knockout cells and with the TOPK inhibitor, OTS964. TOPK depletion altered the G1/S
transition and G2/M arrest in response to radiation. Furthermore, TOPK depletion increased chromosomal aberrations,
multinucleation and apoptotic cell death after irradiation. These results suggest a possible role for TOPK in the radiation-induced
DNA damage checkpoints. These findings have clinical relevance, as elevated TOPK protein expression was associated with
poorer clinical outcomes in prostate cancer patients treated with radical radiotherapy.
Conclusions: This study demonstrates that TOPK disruption may cause tumour-specific radiosensitisation in multiple different
tumour types.
Radiotherapy has a major role in cancer treatment. Increasing
ionising radiation (IR) dose may improve the probability of local
tumour control but increases the risk of damage to the surrounding
healthy tissue. The ‘therapeutic window’ is the range of radiation
doses that can be delivered to patients with limited side effects.
Intrinsic radiosensitivity gives rise to differences in susceptibility
to ionising radiation (IR) treatment and impacts on clinical
endpoints, including survival, local control and disease-free
survival (Hanahan and Weinberg, 2011). Our laboratory developed
a high-throughput colony formation assay (CFA) and screened an
siRNA library of 709 protein kinases (Tiwana et al, 2015), which
identified T-LAK cell-originated protein kinase, TOPK (also
known as PDZ-binding kinase) as a highly ranked radiosensitising
gene. We chose to further investigate TOPK as a potential target to
widen the therapeutic window due to its differential expression
between cancer and normal tissues.
TOPK is a Ser/Thr protein kinase of 322 amino acids first
identified from a lymphokine-activated killer T-cell subtraction
cDNA fragment library (Abe et al, 2000) and as a physical interactor
of the hDlg tumour suppressor protein (Gaudet et al, 2000).
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TOPK is a member of the mitogen-activated protein kinase kinase
family involved in growth, migration and mitotic progression (Abe
et al, 2000; Gaudet et al, 2000; Matsumoto et al, 2004; Shih et al,
2012; Shinde et al, 2013; Park et al, 2006). TOPK activity is regulated
by CDK1/cyclin B-mediated phosphorylation at its Thr9 residue,
which promotes mitotic entry at the G2/M checkpoint (Abe et al,
2000; Gaudet et al, 2000; Matsumoto et al, 2004). TOPK inhibits
PTEN, leading to AKT/PI3K activation (Shih et al, 2012; Shinde
et al, 2013). During mitosis, TOPK phosphorylates histone H3
(Ser10) during the transition from prophase to metaphase, (Park
et al, 2006) specifically targets C2H2 zinc finger proteins to promote
chromatin dissociation (Rizkallah et al, 2015) and complexes
with cyclin B/CDK1 to phosphorylate PRC1 and promote
chromosomal separation and cytokinesis (Abe et al, 2007). TOPK
depletion results in cytokinetic failure and cell cycle arrest, (Abe et al,
2007; Park et al, 2010), which leads to multinucleation in HeLa cells
(Matsumoto et al, 2004). TOPK directly inhibits the tumour-
suppressor p53 with subsequent downregulation of p21 expression
and impaired regulatory control over cellular growth (Zykova et al,
2010).
TOPK is involved in the cellular response to doxorubicin
(Nandi et al, 2007; Zykova et al, 2010), arsenite (As3þ ) (Zykova
et al, 2006) and ultraviolet radiation (Ayllon and O’Connor, 2007),
but has not been studied in the context of IR. Overexpression of
TOPK in HT1080 cells following doxorubicin treatment suppresses
G2/M checkpoint control, leading to premature mitotic entry and
polyploidy (Nandi et al, 2007). Furthermore, TOPK co-localises
with g-H2AX foci after arsenite treatment and inhibits apoptosis in
RPMI-7951 cells (Zykova et al, 2006), and TOPK depletion reduces
the number of g-H2AX foci in MCF-7 cells following UV-induced
DNA damage (Ayllon and O’Connor, 2007).
TOPK expression is upregulated in most cancers (Rhodes et al,
2007); however, expression is restricted in normal tissues to a few
organs such as testis and placenta (Abe et al, 2000; Gaudet et al,
2000; Matsumoto et al, 2004; Fujibuchi et al, 2005). High TOPK
expression has been associated with adverse effects on local tumour
control in non-small-cell lung cancer and with mutant p53
expression levels (Lei et al, 2013; Shih et al, 2012; Lei et al, 2015).
Similarly, high TOPK expression correlates with worse overall
survival and recurrence-free survival in breast, gastric and
colorectal cancer (O’Leary et al, 2013; Xiao et al, 2015; Ohashi
et al, 2017). In colorectal cancer, increased levels of TOPK are
correlated with high levels of interleukin-8 (Xiao et al, 2015) and
with oncogenic KRAS and BRAF mutations (Zlobec et al, 2010). In
prostate cancer, high TOPK expression correlates with increased
invasiveness and cancer stage (Sun et al, 2015). Conversely, low
TOPK expression is predictive of poor prognosis in cholangio-
carcinoma patients (He et al, 2010).
In the present study we report a novel role for TOPK as a
tumour-specific modulator of radiosensitivity. TOPK has the
potential to be exploited as a clinical radiosensitiser due to its
differential expression between cancer and normal tissues. TOPK
depletion impairs G2/M checkpoint activation and increases
chromosomal aberrations, apoptosis and multinucleation. Elevated
TOPK protein expression is associated with poorer clinical
outcomes in a cohort of prostate cancer patients treated with
radical radiotherapy.
MATERIALS AND METHODS
Cell culture. HCT116, HeLa, MRC5, HFL-1, DU145, PC3, H1299
and T24 cell lines were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). SQ2OB cells were
provided by Dr Ralph Weichselbaum (University of Chicago,
Chicago, IL, USA). T24 cells were maintained in RPMI-1640,
MRC5 cells in MEM and HFL-1 cells in DMEM/F-12 Ham’s. The
HAP1 cell lines were purchased from Horizon Discovery
(Cambridge, UK) and maintained in IMDM medium. HAP1 is a
near-haploid human cell line derived from chronic myelogenous
leukaemia cell line. HAP1 cells are adherent with fibroblast-like
morphology. TOPK knockout was achieved via Crispr/Cas9 editing
to contain a 4 bp deletion in the coding exon of TOPK. HUVEC
and HMEC_1 cells were maintained in EBM-Plus (Lonza,
Walkersville, MD, USA) medium. All other cells were maintained
in DMEM. All cells were maintained with 10% FBS and all
medium was purchased from Sigma (St Louis, MI, USA). All cell
lines were authenticated by LGC standards (ATCC) by short
tandem repeat profiling and tested for mycoplasma using
MycoAlert (Lonza).
siRNA transfection. Reverse-transfection protocol was used (final
concentration 20 nM) using Ambion Silencer Select siRNA
(LifeTechnologies) INTERFERin-HTS (Polyplus) transfection
reagent as previously described (Tiwana et al, 2015). siTOPK:
50-GACUAAUGGAUGAAGCUAAtt-30; siTOPK_2: 50-CCCU-
GAGGCUUGUUACAUUtt-30; siTOPK_3: 50-GCACUAAUGAA-
GACCCUAAtt-30.
Cell synchronisation. Cell synchronisation in G1/S phase was
achieved using 2mM thymidine block for 18 h, followed by 9 h
release in fresh medium and then 14 h further incubation with
2mM thymidine. Cells were released in fresh medium after two
washes in PBS.
Immunoblotting. Protein lysates were prepared using RIPA lysis
buffer (Thermo Scientific, Rockford, IL, USA) with protease
inhibitors (Roche, Mannenheim, Germany) and phosphatase
inhibitors (Sigma). Protein concentration was determined using
the BCA assay (Thermo Scientific). Bound antibodies were
detected by developing film from nitrocellulose membranes
exposed to chemiluminescence reagent (Immobilon Western
Chemiluminescent Substrate, EMD Millipore, Merck KGaA,
Darmstadt, Germany).
Antibodies. The following antibodies were used: anti-TOPK for
immunoblotting (Sigma SAB5300406 clone 2C8, 1 : 1000); anti-
TOPK for immunohistochemistry (Cell Signaling Technology,
Danvers, MA, USA 4942, 1 : 100); anti-TOPK (phospho T9)
antibody (Abcam, Cambridge Science Park, Cambridge, UK
ab184953, 1 : 1000); anti-cyclin E1 (Cell Signaling Technology
4129, 1 : 1000); anti-cyclin B1 (Cell Signaling Technology 4138,
1 : 1000); anti-phospho-CDK1 (Tyr15) (Cell Signaling Technology
4539, 1 : 1000); anti-CDK1 (Cell Signaling Technology 9116,
1 : 1000); anti-phospho histone H3 (Ser10) (Cell Signaling
Technology 3377, 1 : 1000); anti-histone H3 (Cell Signaling
Technology 9715, 1 : 1000); anti-Akt (Cell Signaling Technology
9272S, 1 : 1000); anti-phospho-Akt (Cell Signaling Technology
4060S, 1 : 1000); anti-Vinculin (Abcam ab18058, 1:40 000); and
anti-g-H2AX Ser139 (Upstate/Millipore, 05-636, Temecula, CA,
USA).
Colony formation and viability assays. Inhibitor-treated and
siRNA-transfected CFAs were performed and analysed as pre-
viously described (Tiwana et al, 2015). To determine the effect of
OTS964 on cell viability, resazurin was added to the cells for 3 h
after 72 h drug treatment. Fluorescence was measured using a
POLARstar OMEGA plate reader (BMG Labtech, Ortenberg,
Germany). IC50 was calculated from non-linear curve fitting of
Log[Inhibitor] vs Response using variable slope (four parameters;
GraphPad Prism Software v 7.0c, San Diego, CA, USA).
Flow cytometry. Bromodeoxyuridine (BrdU) (20 mM; Sigma) was
added to adherent cells 30min before fixing. Cells were fixed in ice-
cold 70% ethanol, incubated at room temperature with 2M HCl
containing 0.1mgml 1 pepsin for 20min and resuspended in
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100 ml of 2% FBS/1PBS with 1 ml mouse anti-BrdU monoclonal
antibody (1 : 100, BD Bioscience, San Jose, CA, USA) for 90min.
Samples were resuspended in 100 ml 2% FBS/1PBS with 0.5ml
Goat anti-Mouse AF488 antibody (Life Technologies, Eugene, OR,
USA) for 60min in the dark. Samples were washed in PBS and
resuspended in 0.5ml PBS containing 50 mgml 1 propidium
iodide (PI). Samples were analysed using FACSort cytometer
(Becton Dickson, San Jose, CA, USA).
Microscopy. For live cell analysis, cells were stably transfected
with the pH2B_mCherry_IRES_puro2 plasmid (Steigemann et al,
2009) (from Daniel Gerlich, Addgene plasmid 21045). Phase-
contrast and fluorescence images were taken every 30min for 48 h,
with cells maintained at 5% CO2, 37 1C. For fixed cell analysis, cells
were plated onto glass coverslips, fixed with 70% ice-cold methanol
for 10min and then incubated with PBS containing 1mgml 1
DAPI and 1 mgml 1 FITC. Coverslips were then washed and
mounted on a microscope slide using antifade medium Vectashield
(Burlingame, CA, USA). Samples were analysed with a confocal
microscope (Zeiss710, Zeiss, Oberkochen, Germany) and cell
morphology was scored manually using ImageJ open source
software. Mitotic chromosomes were captured by incubating the
cells in colcemid (30 ngml 1) for 1 h and metaphase nuclei
prepared by incubating samples in hypotonic solution (75mM KCl)
for 30min before fixation in Carnoy solution (3 : 1 methanol:glacial
acetic acid). Chromosome suspensions were dropped onto slides
and mounted using Vectashield with DAPI. Samples were imaged
with  100 oil-immersion lens using a Nikon 90i confocal
microscope (Nikon, Minato, Tokyo, Japan).
Patient samples. Prostate cancer samples and associated anon-
ymous follow up data (ORB ethics 09/H0606/5þ 5) included 128
patients who received radical radiotherapy with curative intent. All
patients that participated in the study and whose samples were
used for analysis provided informed signed consent. Prostate
biopsies were collected at the time of diagnosis. External beam
radiotherapy was 3D conformal CT planned. A 55Gy dose was
typically delivered to the planned target volume in 20 fractions
over a 4-week period with neoadjuvant and concurrent androgen
deprivation therapy. Assuming an a/b ratio for prostate cancer of
1.8Gy (Dearnaley et al, 2016), this dose/fractionation schedule is
equivalent to 65.9 Gy in 2Gy fractions. All patients were treated at
the Oxford Cancer Centre and human tissue was used with
National Research Ethics approval (study 07/H0606/120).
Immunohistochemistry. Sections were de-paraffinised in histo-
clear and rehydrated through graded ethanol to water. Endogenous
peroxidase activity was inactivated using 3% H2O2 in methanol.
Sections were blocked with 5% normal goat serum and incubated
with primary antibody at 4 1C overnight. A biotinylated secondary
antibody was added for 45min followed by an avidin/biotin-based
peroxidase solution and incubated with 3,30-diaminobenzidine
solution before counterstaining with haematoxylin. All sections
were dehydrated using increasing percentages of ethanol followed
by histoclear and mounted in omnimount medium.
Scoring and statistical analysis. Patient samples were assigned a
blind intensity score ranging from 0 (no expression) to 3 (maximal
expression) multiplied by the percentage of stained cells (total
TOPK expression score, 0–600). For univariate analysis, data were
initially binarised as described in the text, whereas significance was
assessed using the log-rank test. Cox survival analysis was
performed. Analyses were done using SPSS statistic 22 software
(UNICOM Global, Mission Hills, CA, USA). All statistical tests
were performed as two-tailed tests and differences were considered
significant at a P-value of less than 0.05. All assay data are
representative of three independent experiments and are presented
as mean ± s.d. from triplicate wells, unless otherwise stated
(*Po0.05, **Po0.01 and ***Po0.001). Survival curves were fitted
using nonlinear regression and were analysed by factorial two-way
ANOVA, with interaction term significance of Po0.05.
RESULTS
TOPK is a tumour-specific novel modulator of radiosensitivity.
The impact of TOPK knockdown on radiosensitivity was
investigated in a panel of cancer cell lines using a CFA. Transient
knockdown of TOPK was achieved by siRNA transfection at a final
concentration of 20 nM (siTOPK), with non-targeting siRNA
(siNT) used as a control. Radiosensitisation was observed in all
siRNA treated cancer cell lines, with the survival enhancement
ratio at a SER10 of 1.28 (P¼ 0.007) in HeLa cells (cervical), 1.45
(P¼ 0.002) in HCT116 cells (colorectal), 1.55 (P¼ 0.005) in
DU145 cells (prostate) and 1.45 (Po0.001) in HAP1 TOPK
CRISPR/Cas9 knockout cells (Figure 1A). Four other cancer cell
lines showed similar enhancement ratios: 1.37 (P¼ 0.006) in T24
cells (bladder), 1.28 (P¼ 0.003) in H1299 cells (lung), 1.13
(Po0.001) in SQ20B cells (head and neck) and 1.35 (P¼ 0.004)
in PC3 cells (prostate; Supplementary Figure 1A).
The Oncomine 3.0 database revealed that TOPK expression is
predominantly limited to cancer tissues, with many studies
showing high TOPK expression in tumour types including the
brain, breast and lung (Supplementary Figure 1B; Rhodes et al,
2007). This is in accordance with the undetectable TOPK
expression in MRC5 and HFL-1 normal lung fibroblasts
(Supplementary Figure 1C). Correspondingly, no significant
radiosensitisation was observed in HFL-1 or MRC5 cells,
suggesting that the observed radiosensitising effect is tumour
specific (Figure 1B). Two additional TOPK siRNAs were used in
HCT116 cells to confirm that the radiosensitisation was not due to
an off-target effect (Supplementary Figure 1D). To examine the
effect of TOPK overexpression on colony formation in HCT116
cells, a CFA was performed, which did not affect radiosensitisation
when compared to the empty vector control (Supplementary
Figure 1E), suggesting potential differences between endogenous
and exogenous TOPK expression or the presence of a radio-
resistance threshold that is not altered by further increase in TOPK
levels.
OTS964 is a small molecular compound previously shown to
inhibit TOPK kinase activity (Matsuo et al, 2014). In order to study
the effect of OTS964 on cell viability, the IC50 was determined for a
panel of cell lines treated with the inhibitor for 72 h. In HAP1 WT
and HAP1 TOPK cell lines, the IC50 was 83 nM and 567 nM,
respectively (Supplementary Figure 1F). In addition, the IC50 was
greater in HFL1 and MRC5 cells than any of the tested cancer cell
lines, indicating that cells with high TOPK expression are most
sensitive to the inhibitor (Supplementary Figure 2A). We next
investigated whether treatment with OTS964 could elicit tumour-
specific radiosensitisation comparable to siRNA-mediated TOPK
depletion. Treatment of nocodazole-arrested HCT116 cells with
100 nM or 200 nM OTS964 for 4 h is sufficient to inhibit the TOPK
substrate motif, HpTGEKP, indicating that TOPK is inhibited
under these conditions (Supplementary Figure 2B). Cell lines with
an IC50 of 60 nM or less were treated with 70–100 nM OTS964 and
those with an IC50 above 60 nM were treated with 200 nM OTS964.
The inhibitor was added 4 h before IR and washed off 24 h after IR.
The tested cancer cell lines were radiosensitised (Figure 1C and
Supplementary Figure 2C) with SER10 values of 2.14 (Po0.001) in
HeLa, 1.40 (Po0.001) in HCT116, 1.42 (Po0.001) in DU145, 3.02
(Po0.001) in T24, 1.33 (Po0.001) in H1299, 1.54 (P¼ 0.003) in
SQ20B and 1.34 (Po0.001) in PC3. The normal cell lines tested
were not radiosensitised, with SER10 of 0.90 (P¼ 0.172) in HFL-1,
1.08 (P¼ 0.601) in MRC5 (Figure 1D), 1.04 (P¼ 0.817) in HUVEC
(umbilical vein epithelium) and 1.00 (P¼ 0.466) in HMEC_1
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(microvascular epithelium) Supplementary Figure 2D. These
experiments suggest that TOPK knockdown or kinase inhibition
induces tumour-specific radiosensitisation with minimal effects on
normal tissue cells.
TOPK depletion alters cell cycle progression following IR. In
order to investigate the role of TOPK in the cellular response to IR,
a time-course experiment was conducted to determine cell cycle
progression of HCT116 cells after 4Gy IR. Asynchronous cells
were irradiated 72 h post siRNA transfection. Cell cycle stage was
assessed by flow cytometry analysis using anti-BrdU and PI
staining. At 0 h, TOPK depletion caused only slight changes in cell
cycle distribution, with a 5% increase in the G1 fraction compared
to the control, and 3 and 2% decreases in the early S and G2/M
fractions, respectively (Figure 2A, quantified in Supplementary
Table 1). At 2 h after IR, a 12% increase in the siTOPK G1
population and corresponding decreases of 4 and 3% in the early S,
late S and G2/M populations, respectively, were observed. The
biggest differences were detected at 8 h post IR, with siTOPK cells
showing an 18% increase in G1 phase, a 5% decrease in late S and a
14% decrease in G2/M compared with siNT.
The observed increase in G1 and corresponding decrease in
G2/M following IR in TOPK-depleted cells could be due to delay in
G1 exit, premature mitotic entry, increased cycling rate or a
combination of these factors. To distinguish between these
possibilities, TOPK-depleted HCT116 cells were synchronised in
G1 via double-thymidine block, irradiated at 4Gy and immediately
released into fresh culture medium (Figure 2B and Supplementary
Table 2). Exit from G1 into S-phase was delayed in cells depleted of
TOPK when compared with the control (72% decrease in the G1
population after 2 h for the control cells, but only a 46% decrease in
the G1 population after 2 h for the cells depleted of TOPK
compared to 0 h). Delayed G1 exit in the TOPK knockdown cells
was independent of IR (Figure 2B). The G1 population in the cells
depleted of TOPK was nearly triple that of the control at 8 h after
release. Correspondingly, there was delayed entry into S phase in
irradiated TOPK-depleted cells, with a peak in early S phase at 4 h
of only 29%, compared to a higher peak of 48% at 2 h in the control
cells. The peak in late S phase was at 8 h for both treatments, but
was 45% in the TOPK-depleted cells compared with 66% in the
control cells. Cell cycle distribution was comparable at the 24 h
time point in the presence or absence of IR for all treatments.
These findings are consistent with a delay in G1 exit following
TOPK depletion.
Markers for cell cycle regulation (cyclin B1 and E1, CDK1 and
phospho-CDK1) and mitosis (phosphorylation of histone H3 at
Ser10) were assessed in G1 synchronised HCT116 cells and are
presented in Figure 2C and Supplementary Figure 3A. TOPK
phosphorylation peaked at 8 h post release in the control cells
(Figure 2C). Levels of CDK1 peaked between 6 and 10 h in both the
control and TOPK-depleted cells. However, CDK1 phosphoryla-
tion (Tyr15) was much reduced in the TOPK-depleted cells,
indicating a possible impairment of G2/M checkpoint in these cells.
Expression of the mitotic markers phospho-histone H3 and cyclin
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Figure 1. TOPK is a tumour-specific modulator of radiosensitivity. (A) TOPK was transiently knocked down with siRNA (siTOPK) and post-
irradiation clonogenic survival was assessed in cancer-derived cells. Transfection with siNT was used as a control and knockdown efficiency was
confirmed by immunoblotting (insets). (B) No significant TOPK-dependent radiosensitisation was detected in HFL-1 and MRC5 cells. (C) TOPK
activity was inhibited by 4 h pretreatment with 70–200nM OTS964 (70 nM for HCT116, DU145, 100 nM for HeLa, 200nM for HFL-1, MRC5). (D) No
significant TOPK-dependent radiosensitisation was detected in HFL-1 and MRC5 cells treated with OTS964. All data are representative of three
independent experiments and are presented as mean± s.d. from triplicate wells. Survival curves were fitted using non-linear regression. Results
were analysed by factorial two-way ANOVA, with interaction term significance of Po0.05. PE¼plating efficiency; SER10¼ survival enhancement
ratio at a surviving fraction of 0.10.
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B1 peaked at 10 h post-release in the control cells, reflecting a
coordinated progression into mitosis (Figure 2C and
Supplementary Figure 3A). In contrast, post-release mitotic entry
occurred earlier for cells depleted of TOPK, with H3 phosphoryla-
tion and cyclin B1 expression occurring earlier at 6–8 h post
release, despite the delayed G1 exit (Figure 2C). Cyclin E1
expression confirmed enrichment of G1/early S phase cells at the
earliest time points (T¼ 0 and T¼ 2) in the control sample,
decreasing post release and reappearing at the latest time point
(T¼ 24), indicating a return to G1. However, cyclin E levels did not
decrease as rapidly in the TOPK-depleted cells, consistent with a
delay in G1 exit. TOPK has been previously shown to have a role in
the PI3K/Akt pathway (Ayllon and O’Connor, 2007), the levels of
phospho-Akt were therefore investigated after IR and did not show
a significant dependency on the levels of TOPK (Supplementary
Figure 3B). These results are consistent with both a delay in G1 exit
and an impaired G2/M transition in TOPK-depleted cells.
TOPK depletion promotes multinucleation and apoptosis after
IR. Altered cell cycle progression and failure to activate DNA
damage checkpoints can result in chromosomal aberrations,
mitotic catastrophe, micronucleation, multinucleation and apop-
tosis (Dillon et al, 2014; Visconti et al, 2016). To determine the
consequences of altered cell cycle progression and G2/M arrest in
TOPK-depleted cells, we performed live-cell imaging using
HCT116 H2B-mCherry cells. The cells were transfected with siNT
or siTOPK, and after 72 h were exposed to 4Gy IR. Cells were then
imaged every 30min for 48 h. The fate of 50 cells was determined
for each experimental replicate and transitions through mitosis and
interphase were recorded (Figure 3A and Supplementary Movies
1–4). There was no significant difference in the length of mitosis, as
the first mitosis was 1.9 h in the control cells compared to 1.5 h in
the TOPK-depleted cells (P¼ 0.231). However, in TOPK-depleted
cells there was a significant 8% increase (P¼ 0.024) in the number
of cells that entered mitosis, attempted cell division and then
became multinuclear during the first division (Figure 3B).
Furthermore, a nonsignificant 3% increase in apoptosis was
observed in TOPK-depleted cells before the first mitosis
(P¼ 0.705) and a significant 14% increase in apoptosis was
observed in the daughter cells prior to the second mitosis
(P¼ 0.001).
To fully evaluate the impact of this finding at later time-points,
we quantified irradiation-induced multinucleation in fixed
HCT116 cells following TOPK knockdown using DAPI and FITC
as nuclear and cytoplasmic stain. TOPK knockdown resulted in a
significantly higher number of multinucleated cells (Po0.01)
following irradiation, but no differences were observed in
unirradiated cells (Figure 3C). To further investigate the increase
in apoptosis in irradiated TOPK-depleted cells, Hoechst and
Annexin V assays were used to monitor apoptotic cell death at 24,
48 and 72 h after 4Gy IR. In both cases, TOPK knockdown caused
a significant increase in the percentage of apoptotic cells at the
latest time points compared to the siNT control (Figure 3D,
Supplementary Figure 3C and Supplementary Table 3). The same
result was reproducible using siTOPK_2 and siTOPK_3 siRNAs for
the Hoechst assay (Supplementary Figure 3D). Taken together,
these data suggest that irradiation of TOPK-depleted cells results in
post-mitotic chromosomal instability, multinucleation and ulti-
mately apoptotic cell death.
TOPK depletion causes chromosomal aberrations in response to
IR. In order to test whether TOPK-dependent radiosensitisation
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Figure 2. TOPK depletion alters cell cycle progression following IR. Bromodeoxyuridine (BrdU) was added to cells 30min before fixation and cell
cycle stage was assessed by flow cytometry analysis using anti-BrdU and PI staining. The impact of TOPK depletion by siRNA on cell cycle
progression was assessed in asynchronous HCT116 cells (A) and in HCT116 cells released from double thymidine block (B) following 4Gy
irradiation at T¼0. Numbers indicate the percentage G1 population (PI /BrdU , lower left quadrant) or G2/M population (PIþ /BrdU , lower
right quadrant). Early S (BrdUþ /PI , top left quadrant). Late S (BrdUþ /PIþ , top right quadrant). (C) Immunoblotting was used to assess the
effect of TOPK knockdown on the expression of cell cycle proteins in samples from the experiment described in (B). Vinculin was used as a loading
control. Data displayed are representative of three independent repeats.
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was due to erroneous DNA repair, post-IR DNA damage was
compared in TOPK knockdown cells and control cells using an
alkaline Comet assay. No differences in DNA damage were
detected at 30min, 2 or 8 h after 4Gy IR (Supplementary
Figure 3E). The kinetics of g-H2AX foci formation and resolution
was then assessed after 4Gy IR. Although a small statistically
significant decrease in the number of foci was identified in
TOPK-depleted cells at 30min post IR, this was not observed at 4,
8 and 24 h post IR (Supplementary Figure 3F). These results
suggest that TOPK does not affect double strand break (DSB)
repair.
To investigate whether TOPK knockdown could induce mitotic
progression errors, metaphase spreads were prepared in HCT116
cells with siNT or siTOPK knockdown and the number of
aberrations present per genome were quantified at 24, 48 and 72 h
after 4Gy IR (Figure 4A). Chromosomal aberrations such as
breaks, exchanges and fragmentation were significantly greater in
TOPK-depleted cells when compared with the control at all time
points (Figure 4B).
TOPK levels affect survival in prostate cancer patients after
radiotherapy. To examine the clinical relevance of our findings,
the relationship between TOPK expression and therapeutic efficacy
was studied in a cohort of 128 prostate cancer patients treated with
radical radiotherapy. Over a median (interquartile range) follow-
up period of 7.7 (6.9–8.4) years following radical radiotherapy,
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Figure 3. TOPK depletion causes multinucleation and apoptosis in HCT116 cells. Cells were irradiated 72h post siRNA treatment. (A) Live-cell
imaging following the fate of 50 HCT116 H2B-mCherry cells for 48 h after 4Gy IR. Each horizontal bar represents one cell, with interphase shown in
grey and mitosis shown in black. Following division, the first daughter cell to undergo division, apoptosis or multinucleation is shown. (B) The
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(C) Analysis of IR-induced multinucleation in fixed HCT116 treated cells 72 h after 4Gy IR. At least 100 cells were counted per condition. Nuclei
were stained with the DAPI DNA stain (blue) and FITC was used as a cytoplasmic counterstain (green). (D) Cell death in the presence (right panel)
and absence (left panel) of 4Gy irradiation was assessed with Hoechst staining to identify bright apoptotic nuclei in cells transfected with NT or
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prostate cancer had recurred in 62/128 (48%) patients, of whom
44/128 (34%) had non-metastatic recurrence and 18/128 (14%)
had metastatic recurrence. Deaths from any cause during the
follow-up period occurred in 26/128 (20%) patients.
Immunohistochemistry was used to measure TOPK expression
from archived prostate biopsies taken at diagnosis and results were
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Figure 4. High TOPK expression correlates with poor outcomes in prostate cancer patients. (A) HCT116 cells were transfected with
siRNA and irradiated (4Gy). Metaphases were collected at 24, 48 and 72 h following irradiation and scored for chromosomal aberrations, with
40 nuclei analysed in each group. Images of representative metaphases include examples of typical errors detected (insets). Arrows indicate
chromosomal aberrations. (B) Average number of errors per metaphase from three independent experiments *Po0.05 and **Po0.01.
(C) Representative photomicrographs taken following immunohistochemistry staining with an anti-TOPK antibody, showing non-staining in
disease-free prostate epithelium and strong nuclear and cytoplasmic TOPK expression in prostatic carcinoma. (D) Kaplan–Meier analysis of TOPK
expression and overall survival, and any recurrence in prostate cancer patients following radical radiotherapy (n¼ 128). P-value from univariate
analysis.
Table 1. Diagnostic biopsy pathology characteristics of 128
prostate cancer patients at baseline
Category N (%)
Pre-treatment PSA
p10 46 (35.9)
10.1–20 43 (33.6)
X 20 32 (25)
Unknown 7
Clinical T stage
p 2 78 (60.9)
X 3 42 (32.8)
Unknown 8 (6.3)
Gleason grade
p 6 30 (23.4)
7 83 (64.9)
X 8 15 (11.7)
Abbreviation: PSA¼prostate specific antigen.
Table 2. Multivariate analysis of clinical prognostic factors for
the development of prostate cancer recurrence and any-
cause death
Any recurrence Any-cause death
HR (95% CI) P HR (95% CI) P
All prostate cancer cases
cT stage 1.33 (0.77–2.3) 0.3 0.63 (0.26–1.56) 0.32
PSA 1.07 (0.77–1.48) 0.7 0.86 (0.51–1.46) 0.58
Primary GleasonX4 1.72 (1.01–2.93) 0.048 2.2 (0.93–5.2) 0.07
Total TOPK 1.73 (1.02–2.92) 0.04 1.65 (0.72–3.8) 0.24
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; PSA¼prostate specific antigen.
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analysed with respect to clinical outcomes including recurrence-
free survival (RFS) and all-cause mortality. Diagnostic biopsy
pathology characteristics of the patient cohort at baseline can
be found in Table 1. Samples were ranked according to the
levels of TOPK expression and the median of the ranking
values was used as a cut-point score for high and low TOPK
protein expression (Figure 4C). Multivariate analysis was per-
formed to test whether TOPK expression could be a prognostic
factor for post-radiotherapy prostate cancer recurrence as
presented in Table 2. High levels of TOPK expression in
malignant prostate epithelium in diagnostic prostate biopsies
at baseline was significantly associated with a reduced RFS
following radical radiotherapy (P¼ 0.020). No significant
association was observed between levels of TOPK expression
and all-cause mortality (Figure 4D). These results indicate that
TOPK levels may affect radiotherapy outcome for prostate cancer,
and that analysis of TOPK levels might be clinically useful as
a prognostic marker when considering treatment with
radiotherapy.
DISCUSSION
TOPK depletion radiosensitised a panel of cancer cell lines derived
from lung, prostate, cervical, bladder and laryngeal cancers. This
effect was independent of p53 status for the cancer cell lines tested,
although most of these cell lines are deficient in p53
(Supplementary Table 4). Radiosensitisation was reproducible with
siRNAs targeting multiple TOPK sequences and no radiosensitisa-
tion was observed in normal cells following TOPK knockdown.
Comparable results were obtained with the TOPK inhibitor,
OTS964. These data indicate that TOPK is a tumour-specific
modulator of radiosensitivity.
Depletion of cell cycle regulators can cause radiosensitisation
(Ayllon and O’Connor, 2007; Dou et al, 2015; Lei et al, 2015). In
support of this argument, cell cycle regulatory kinases including
CDC2, ATM, CDKN2B, CDK5R1 and PLK4 were highly ranked in
the screen that identified TOPK (Tiwana et al, 2015). Alterations of
cell cycle progression in TOPK-depleted cells could be due to delay
in G1 exit, premature mitotic entry, increased cycling rate or a
combination of these factors. Correspondingly, TOPK-depleted
synchronous cells that were irradiated in G1 and subsequently
released had delayed G1 exit and an impaired G2/M transition. This
is consistent with previous findings that TOPK ensures proper
arrest at the G2/M checkpoint in unirradiated cells (Abe et al,
2000; Gaudet et al, 2000; Matsumoto et al, 2004). Furthermore,
TOPK-depleted cells had increased chromosomal aberrations
in metaphase, including DNA breaks, chromatid exchanges
and DNA fragmentation after IR. The chromosomal aberrations
do not seem to arise from a DNA repair defect in TOPK-depleted
cells. We propose that these aberrations arise as a consequence
of premature mitotic entry, a phenotype that has been observed
in ataxia telangiectasia cells, which are deficient in G2/M
checkpoint activation, but exhibit wild-type levels of chromosomal
breaks in G2 following IR (Terzoudi et al, 2005; Deckbar et al,
2007). Failure of cells to arrest at the G2/M checkpoint leads
to premature chromatin condensation and conversion of
unrepaired DSBs into chromosomal breaks, as DSB repair is
suppressed during mitosis (Orthwein et al, 2014). It is also
possible that the chromosomal aberrations arise partly due to
inappropriate transition from prophase to metaphase or the
inability of C2H2 zinc finger proteins to dissociate from
chromatin, as roles for TOPK in these early mitotic activities
have been described previously (Park et al, 2006; Rizkallah et al,
2015).
The studies of both live and fixed cells suggest that a proportion
of TOPK-depleted cells attempt mitosis and then become multi-
nuclear during both the first division and during subsequent
divisions up to 72 h after IR. Furthermore, a proportion of TOPK-
depleted cells divide at least once and then undergo apoptosis
during interphase. It is our conjecture that the increases in
multinucleation and apoptosis are the consequences of altered cell
cycle progression, failure to activate the G2/M checkpoint and
chromosomal aberrations, causing an increase in radiosensitivity. It
is possible that the chromosomal aberrations observed during the
first mitosis after IR are inherited by the daughter cells, leading to
apoptosis. These findings are consistent with other cell cycle
regulation genes that are modulators of radiosensitisation. For
example, disruption of the G2/M checkpoint protein 14–3–3s
promotes early mitotic entry in response to IR, resulting in mitotic
catastrophe and cell death (Andreassen et al, 2001; Hanahan
and Weinberg, 2011). Inhibition of other DNA damage
checkpoint proteins such as CHK1 and Wee1 also radiosensitise
p53-deficient cells, leading to premature mitotic entry and
apoptosis (Garrett and Collins, 2011). TOPK is phosphorylated
at Thr9 in G2 by cyclin B1/CDK1 to promote mitotic entry and
as such is also considered to be a G2/M checkpoint protein
(Abe et al, 2000; Gaudet et al, 2000; Matsumoto et al, 2004).
Therefore, it is likely that there is a common mechanism of
radiosensitisation following depletion of G2/M checkpoint pro-
teins, including TOPK.
Previous studies have demonstrated a link between high
TOPK expression and poor clinical outcomes in different
types of cancer, and that TOPK is expressed at low levels in most
normal tissues (Rhodes et al, 2007; Lei et al, 2013, 2015; Park et al,
2014; Xiao et al, 2015; Ohashi et al, 2017). Therefore there is
much interest in TOPK as a potential therapeutic target. Our study
shows an increased rate of radiotherapy failure in tumours
with elevated TOPK expression at baseline, which implies
that TOPK expression is an important factor in tumour radio-
resistance. However, analysis of tumour samples taken as part
of a randomised trial of radiotherapy would be required
to definitively confirm TOPK expression as a predictive biomarker.
Overall survival did not show any significant correlation with
levels of TOPK; however, follow-up data did not distinguish
between cancer-specific deaths and all-cause deaths and there were
few deaths overall. Therefore, it is not possible to state whether
TOPK expression influenced overall prostate cancer-specific
survival.
Strong correlations between high levels of TOPK and an
advanced grade of cancer, metastasis and invasiveness have
previously been identified in prostate cancer patients (Brown-
Clay et al, 2015; Sun et al, 2015). Our results support these
investigations, revealing a significant association between high
TOPK expression and disease recurrence, and add a further
level of therapeutic potential by showing these results in the
context of radiotherapy. Encouragingly, our study demonstrates
that inhibition of TOPK activity is a sensitive and tumour-
specific means for enhancing radiosensitivity. As such, the
development of small molecule compounds directed against
TOPK, such as OTS964, may be a future strategy for
enhancing the efficacy of radiotherapy treatment in prostate
cancer patients.
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